APRE - CIK 0001781983
Aprea Therapeutics, Inc. has filed 425 documents with the SEC between 2019 and 2026. The most frequent type is insider trade (144 filings), alongside the regular cadence of annual reports, quarterly reports, and event disclosures every public company must make. Use the filters to focus on one filing type, or flip the sort to trace the company's history from its earliest paperwork.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Filing | Type | Filed | Period covered |
|---|---|---|---|
| Major company event | 8-K | 2025-10-24 | 2025-10-24 |
| Major company event | 8-K | 2025-10-15 | 2025-10-15 |
| Major company event | 8-K | 2025-09-08 | 2025-09-08 |
| SCHEDULE 13G/A | - | 2025-08-13 | - |
| Quarterly report | 10-Q | 2025-08-12 | 2025-06-30 |
| Major company event | 8-K | 2025-08-12 | 2025-08-12 |
| Insider trade | 4 | 2025-06-09 | 2025-06-05 |
| Insider trade | 4 | 2025-06-09 | 2025-06-05 |
| Insider trade | 4 | 2025-06-09 | 2025-06-05 |
| Insider trade | 4 | 2025-06-09 | 2025-06-05 |
| Insider trade | 4 | 2025-06-09 | 2025-06-05 |
| Insider trade | 4 | 2025-06-09 | 2025-06-05 |
| Insider trade | 4 | 2025-06-09 | 2025-06-05 |
| Major company event | 8-K | 2025-06-09 | 2025-06-05 |
| Insider trade | 4 | 2025-06-09 | 2025-06-05 |
| Quarterly report | 10-Q | 2025-05-14 | 2025-03-31 |
| Major company event | 8-K | 2025-05-14 | 2025-05-14 |
| SCHEDULE 13G/A | - | 2025-05-14 | - |
| Annual report to shareholders | ARS | 2025-04-22 | 2024-12-31 |
| Proxy materials | DEFA14A | 2025-04-22 | - |
| Proxy statement | DEF 14A | 2025-04-22 | 2025-06-05 |
| SCHEDULE 13G/A | - | 2025-04-08 | - |
| Insider trade | 4 | 2025-04-04 | 2025-04-03 |
| Insider trade | 4 | 2025-03-31 | 2025-03-27 |
| Insider trade | 4 | 2025-03-31 | 2025-03-27 |
| Annual report | 10-K | 2025-03-25 | 2024-12-31 |
| Major company event | 8-K | 2025-03-25 | 2025-03-25 |
| SCHEDULE 13G/A | - | 2025-02-13 | - |
| SCHEDULE 13G/A | - | 2025-02-10 | - |
| SCHEDULE 13G/A | - | 2025-02-10 | - |
| Major company event | 8-K | 2025-02-05 | 2025-02-05 |
| Major company event | 8-K | 2025-01-13 | 2025-01-13 |
| SCHEDULE 13G | - | 2024-11-14 | - |
| Major company event | 8-K | 2024-11-08 | 2024-11-08 |
| Prospectus supplement | 424B5 | 2024-11-08 | - |
| Major company event | 8-K | 2024-11-07 | 2024-11-07 |
| Quarterly report | 10-Q | 2024-11-07 | 2024-09-30 |
| Insider trade | 4 | 2024-10-25 | 2024-10-18 |
| Insider trade | 4 | 2024-10-24 | 2024-10-23 |
| Major company event | 8-K | 2024-10-23 | 2024-10-23 |
| Insider trade | 4 | 2024-10-17 | 2024-10-16 |
| Insider trade | 4 | 2024-10-16 | 2024-10-15 |
| Insider trade | 4 | 2024-10-16 | 2024-10-14 |
| Insider trade | 4 | 2024-10-16 | 2024-10-11 |
| Insider trade | 4 | 2024-10-15 | 2024-10-11 |
| Insider trade | 4 | 2024-10-15 | 2024-10-10 |
| Insider trade | 4 | 2024-10-15 | 2024-10-10 |
| Passive ownership stake | SC 13G | 2024-10-10 | - |
| Major company event | 8-K | 2024-10-09 | 2024-10-09 |
| Employee stock plan | S-8 | 2024-08-21 | - |